Bobby Sandage
Chief Executive Officer at Euclises Pharmaceuticals, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Noah Beerman | M | 62 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA.
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 17 years |
Lu Alleruzzo | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 15 years |
Julia Novina | F | - |
Microbial Machines, Inc.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 5 years |
Christopher Bahl | M | - |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 3 years |
Tomas Hode | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 15 years |
Drew Dennison | M | - |
Lightchain Capital LLC
Lightchain Capital LLC Internet Software/ServicesTechnology Services Lightchain Capital LLC operates as single family office of Rodger Riney. It offers venture capital, software development and data science and has worked for major banks, investment firms and startups. The company was founded by Leo Semmelmann and Jan-Erik Flentje in 2007and is headquartered in St. Louis, MO.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 3 years |
Elise Hoffman | F | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 9 years |
Peter Yurkovich | M | - |
Electronic Drug Information Systems Solutions LLC
Electronic Drug Information Systems Solutions LLC Packaged SoftwareTechnology Services Electronic Drug Information Systems Solutions LLC develops electronic drug information systems solutions. It operates a platform that gathers, filters, combines, and presents pharmaceutical intelligence. The firm provides data integration, analytics & presentation, forecasting, and project ranking services. The company is headquartered in St. Louis, MO. | - |
Dominique Verhelle | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
Rajesh Devraj | M | - |
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO. | - |
John J. Talley | M | - |
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO. | 13 years |
Laurence J. Blumberg | M | 62 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 3 years |
Vuong Trieu | M | 59 | 5 years | |
Carl Novina | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
Charlie Bolten | M | - |
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Matt Phimphavong | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 3 years |
Clifford Holekamp | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 12 years |
Andrew Barnell | M | - |
Geneoscopy, Inc.
Geneoscopy, Inc. Miscellaneous Commercial ServicesCommercial Services Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO. | 9 years |
Kyle Kerns | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 5 years |
Yiming Kang | M | - |
Geneoscopy, Inc.
Geneoscopy, Inc. Miscellaneous Commercial ServicesCommercial Services Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO. | 9 years |
Erica Barnell | F | - |
Geneoscopy, Inc.
Geneoscopy, Inc. Miscellaneous Commercial ServicesCommercial Services Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO. | 9 years |
Paul Meier | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 5 years |
Brian Matthews | M | 66 |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 12 years |
Malcolm Salter | M | 84 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 3 years |
Kenneth Gruber | M | - |
Endevica Bio
Endevica Bio BiotechnologyHealth Technology Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020. | 15 years |
Kenneth Anderson | M | 72 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
Rick Ryan | M | - |
Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals, Inc. Hospital/Nursing ManagementHealth Services Euclises Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm develops a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib platform and is in the process of selecting a lead clinical development candidate. The company was founded by John J. Talley in 2011 and is headquartered in St. Louis, MO.
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 11 years |
Barry A. Polisky | M | 78 |
Microbial Machines, Inc.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
David Smoller | M | 60 |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI.
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 12 years |
Daniel Marks | M | - |
Endevica Bio
Endevica Bio BiotechnologyHealth Technology Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020. | - |
Donnie Hardison | M | 73 |
Geneoscopy, Inc.
Geneoscopy, Inc. Miscellaneous Commercial ServicesCommercial Services Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO. | 1 years |
John McKearn | M | 70 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
Russ Potterfield | M | - |
Endevica Bio
Endevica Bio BiotechnologyHealth Technology Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020. | 4 years |
Kyle Welborn | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 12 years |
Jeffrey Wagner | M | - |
Microbial Machines, Inc.
| 5 years |
Graham Peck | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 6 years |
Martha Gallagher | F | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 7 years |
Andrea Armstrong | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
Bill Schmidt | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 11 years |
Rick Ryan | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 11 years |
Eric Pham | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
Matt Badler | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Marc Hirshman | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Jonathan Fritz | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Lori Friedman | M | 60 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 1 years |
Cathy Folster | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
Christine Henderson | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Kristina Barrett | F | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 5 years |
Joyce O'Shaughnessy | F | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
Michel Ducreux | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
Susan Langer | F | 33 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
Scott Addonizio | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Bruce Evans | M | 64 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | - |
Dave Messina | M | - |
Geneoscopy, Inc.
Geneoscopy, Inc. Miscellaneous Commercial ServicesCommercial Services Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO. | 7 years |
Dennis Muilenburg | M | 60 |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Remi Barbier | M | 64 |
Bioventures LLC
Bioventures LLC Pharmaceuticals: MajorHealth Technology Bioventures LLC is a pharmaceutical company that develops pharmaceutical products. The private company is based in Tulsa, OK and was founded in 2004. | - |
Mark Alles | M | 64 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 1 years |
Arthur Becker | M | 74 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
William McKee | M | 62 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Carole Nüchterlein | F | 62 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 8 years |
Fred H. Mermelstein | M | 64 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
James Merselis | M | 70 |
Geneoscopy, Inc.
Geneoscopy, Inc. Miscellaneous Commercial ServicesCommercial Services Geneoscopy LLC develops diagnostics It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. The firm provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. The company was founded by Andrew Barnell, Erica Barnell and Yiming Kang in 2015 and is headquartered in Saint Louis, MO. | 6 years |
Catherine Matthes | F | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Elena Prokupets | M | 69 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Joe Biller | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
Sean Morris | M | 52 |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Ronald A. Krasnow | M | 61 |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 4 years |
Todd Kaloudis | M | - |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 2 years |
Dan Bemus | M | - |
Electronic Drug Information Systems Solutions LLC
Electronic Drug Information Systems Solutions LLC Packaged SoftwareTechnology Services Electronic Drug Information Systems Solutions LLC develops electronic drug information systems solutions. It operates a platform that gathers, filters, combines, and presents pharmaceutical intelligence. The firm provides data integration, analytics & presentation, forecasting, and project ranking services. The company is headquartered in St. Louis, MO. | - |
Mark Bakken | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Grant Pothast | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Kyle Rasbach | M | - |
Arch Oncology, Inc.
Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | - |
Dean VandeKamp | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 11 years |
Chris Danforth | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 11 years |
Siu Kit Lam | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Alain J. Cohen | M | 57 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Barry Sandweiss | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | - |
Timothy Stern | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 24 years |
Theresa Visarius | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Andy Dearing | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 5 years |
Robert Nordquist | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Chen Wei | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Joseph Raker | M | - |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Glenn L. Cooper | M | 71 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 20 years |
Charles Casamento | M | 78 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 8 years |
Robyn Hunter | F | 62 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 14 years |
David Chaplin | M | 68 | 6 years | |
Michael Rogers | M | 64 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 13 years |
Dale Ritter | M | 73 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 18 years |
Thomas Forest Farb | M | 67 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 8 years |
Harlan Weisman | M | 71 | 1 years | |
Philip Young | M | 66 | 5 years | |
Tamar Howson | F | 75 | 8 years | |
Caroline B. Manogue | F | 55 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | - |
Xiao Qin Lu | M | 49 | 5 years | |
David Barrett | M | 48 | - | |
Gary Gemignani | M | 58 | 1 years | |
Baxter Phillips | M | 48 | 4 years | |
Rick Holton | M | - |
Cultivation Capital LLC
Cultivation Capital LLC Investment ManagersFinance Cultivation Capital LLC (Cultivation Capital) is a venture capital firm founded in 2012 by Brian Matthews, Cliff Holekamp, Jim McKelvey, Kyle Welborn, and Peter Esparrago. The firm is headquartered in St. Louis, Missouri. | 5 years |
Matthew M. Loar | M | 61 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 97 | 97.00% |
Ireland | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bobby Sandage
- Personal Network